Status:
RECRUITING
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
Lead Sponsor:
West China Second University Hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
Brief Summary
Ovarian cancer ranks third in the incidence of gynecologic malignancies, while mortality ranks first. The tumor marker CA125 is the most concerned tumor marker in the clinical monitoring prognosis of ...
Eligibility Criteria
Inclusion
- Age 18-75;
- Pathologically confirmed ovarian cancer;
- CA125 ≤200U/ml at first diagnosis or recurrence;
- Physical condition score PS ≤ 2 points;
- Enough tumor samples for WES detection;
- Patients and their families can understand and are willing to participate in this study and provide written informed consent.
Exclusion
- Patients unable to provide sufficient tissue / blood samples for research detection;
- Pregnant or lactating women;
- Other diseases considered by the research doctor to affect the prognosis and survival;
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06182917
Start Date
October 1 2023
End Date
June 30 2026
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
west china second University， SICHUAN University, China
Chengdu, Sichuan, China, 610016